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Abstract
Introduction. Esophagectomy is the standard surgical treatment for resectable esophageal cancer patients. However, the success rate for this procedure was about 25–
35% and was associated with a severe risk of postoperative complications. In addition, patients after esophagectomy have decreased their quality of life (QOL), but no
research has been done in Indonesia. Therefore, this study was conducted to determine the quality of life after esophagectomy in Indonesia based on the patient population
at Dr. Cipto Mangunkusumo General Hospital (CMGH).
Method. A retrospective study was conducted using quality–of–life instruments issued by the European Organization for Research and Treatment of Cancer (EORTC).
It consists of the module for esophageal cancer EORTC–QLQ–OES18 and the core questionnaire C30. Subjects were patients after esophagectomy in 2015–2021 at
CMGH.
Results. About 35 subjects underwent esophagectomy and followed by reconstruction, which comprised 62.9% males and 37.1% females. The mean age was 43.8 +
13.1 years. All subjects' median global health was 83.3 (IQR: 25.0). The overall functional scale question item with the lowest score was cognitive functioning (CF) 66.7
(IQR: 50.0). Meanwhile, based on the question items on the overall symptom scale, the worst scores were nausea and vomiting (NV) 16.7 (IQR: 50.0), pain (PA) 16.7
(IQR: 33.3), dysphagia (OESDYS) 33.3 (IQR: 33.3), eating (OESEAT) 34.5 (IQR: 23.9), choking (OESCH) 33.3 (IQR: 33.3), and coughing (OESCO) 33.3 (IQR:
33.3).
Conclusion. The overall QOL after esophagectomy at CMGH based on the EORTC–QLQ–C30 and OES18 questionnaires was good. However, prognostic factors
associated with decreased quality of life should be better educated to patients and prepared well before the esophagectomy procedure, thus maximizing quality of life
after esophagectomy.
Keywords: quality of life, esophagectomy, esophageal cancer

Introduction
Esophageal cancer is one of the malignancies in the gastrointestinal tract
that has a poor prognosis with a five–year survival rate of only 15–50%.
The incidence of esophageal cancer has continued to increase in recent
decades.1–3 About 450,000 people worldwide have esophageal cancer.
The high number of patients with esophageal cancer places it as the
seventh most common malignancy and the sixth leading cause of death
worldwide.4 Two geographic lines have the highest incidence. Firstly,
the "Asian esophageal cancer belt" stretches from northeastern China to
the Middle East, with an incidence of 100 cases per 100,000 people
annually. Secondly, the path runs from east to south Africa.5,6 The
squamous cell carcinoma type predominates in China, unlike most
western countries.6,7 In the United States, the adenocarcinoma type is
dominated by the incidence in Caucasian men of 0.4 per 100 thousand
people in 1973 and increased to 2.8 per 100 thousand people in 2012.5
Based on data from Globocan 2020, the number of esophageal cancer
in Indonesia reached 1,327 new cases and caused the death of up to
1,283 people.8 The number of cases of esophageal malignancy in Dr.
Cipto Mangunkusumo General Hospital (CMGH) in 2020, 12 cases
were reported. The surgical procedures performed are laparotomy to
thoracolaparotomy esophagectomy.
Esophagectomy is the standard surgical procedure for resectable
esophageal cancer. However, the success rate for this procedure is only
between 25—35% and is associated with a severe risk of postoperative
complications.9–11 Patients after esophagectomy are known to have
decreased quality of life (QOL) based on the assessment of physical
function, role function, social function, vitality score, and health
perception.12–14 These patients reported many complaints of weakness,
difficulty breathing, reflux, diarrhea, loss of appetite, nausea, and
vomiting.15–18 On the other hand, several QOL parameters increase after

esophagectomy. For example, pain relief, mental health, emotional,
social, and cognitive function.12–14,17,19,20 Meanwhile, surgical techniques
still provide various QOL outcomes.2,21 Subject characteristics such as
age, gender, and body mass index were also not associated with quality
of life. However, stage III to IV tumors, tumor location, and
postoperative complications were predictors of decreased patient QOL
scores.22,23
No studies in Indonesia have published the quality of life in patients after
esophagectomy. Most patients with esophageal cancer must be referred
to a tertiary–level health facility because it requires more complex
expertise and resource facilities. Therefore, this study was conducted to
determine the quality of life after esophagectomy using instruments
issued by the European Organization for Research and Treatment of
Cancer (EORTC). It consists of the module for esophageal cancer
EORTC–QLQ–OES18 and the core questionnaire C30. The
questionnaire instrument will be used to assess the quality of life in the
patient after esophagectomy, followed by esophageal reconstruction at
Dr. Cipto Mangunkusumo General Hospital (CMGH), Jakarta.
Method
This retrospective cohort study included all adult patients after the
esophagectomy procedure at Dr. Cipto Mangunkusumo National
General Hospital (CMGH). Adult males and females underwent
esophagectomy followed by reconstruction procedure (gastric pull–up,
jejunal conduit, colon conduit, or distal gastroesophageal anastomosis)
at CMGH between 2015–2021 were included in the study. Those with
other malignancies (other than esophageal malignancies) and other
surgical procedures (other than esophagectomy) were excluded from
this study. Demographical data such as age, gender, body mass index,
indication for surgery, tumor stage, tumor location, histopathological cell
type, esophagectomy type, chemotherapy, and reconstruction type were
recorded.
1
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Quality of life was assessed using a questionnaire from the European
Organization for Research and Treatment of Cancer (EORTC). Patients
were asked to fill out the Indonesian version of the EORTC–QLQ–C30
and OES18 questionnaires. In addition, subjects agreed to be
interviewed by telephone or other communication methods (WhatsApp
call/video, Zoom meeting). This questionnaire and its scoring manual
are
available
on
the
EORTC
website
(https://qol.eortc.org/questionnaires/)
used
with
permission.
Unfortunately, no Indonesian version of the OES18 questionnaire is
available. Thus, we provided the translation through a procedure
following the EORTC manuals, adapted from the EORTC translation
procedure published by Koller et al.24 The process consists of drafting,
forward translation, backward translation, and final discussion. Finally,
the translation results are sent to an external proofreading agency.
Furthermore, a pilot study was carried out on ten subjects.

item had the lowest median value, 66.7 (IQR: 50.0). The interpretation
of the score on the functional scale, if it is close to 100, indicates that the
function is getting better. Meanwhile, based on the symptom scale group
on the C30 questionnaire, which consists of items fatigue (FA), dyspnea
(DYS), insomnia (SL), appetite loss (AP), constipation (CO), diarrhea
(DI), financial difficulties (FI) had a median value range of 0.0 (IQR:
0.0) to 0.0 (IQR: 66.7). Only nausea and vomiting (NV) and pain (PA)
items had the highest median scores, 16.7 (IQR: 50.0) and 16.7 (IQR:
33.3), respectively. The interpretation of the score on the symptom scale,
if it is close to 0, indicates the symptoms the patient complains of are
getting lower. Meanwhile, based on the OES18 questionnaire, item
eating (OESEAT) had the highest median score, which was 34.5 (IQR:
23.9). Meanwhile, the items with a median score of zero number were
trouble swallowing saliva (OSSV), dry mouth (OESDM), taste
(OESTA), and speech (OESSP).

All data were analyzed using IBM Statistical Package for the Social
Sciences (SPSS) version 20. The normality test of data distribution used
the Shapiro–Wilk test because the number of subjects was ≤50.
Numerical variables were expressed as mean (standard deviation, SD)
or median (interquartile range, IQR). Categorical variables were
presented as frequency (percentage). The normal distribution data were
analyzed using the unpaired t–test (the independent variable with two
groups) or one–way ANOVA (>2 groups). Alternatively, if the data
distribution was not normal, then an alternative nonparametric Mann–
Whitney test (two groups) or Kruskal–Wallis (>2 groups) was
performed. Categoric variables in the 2x2 table were analyzed using the
Chi–square test. The Committee of ethics, Faculty of Medicine,
Universitas Indonesia, approved the study number KET–
212/UN2.F1/ETIK/PPM.00.02/2022, protocol number 22–02–0228.

Table 1. Subjects’ characteristic

Results
Thirty–five subjects underwent esophagectomy and esophageal
reconstruction at CMGH from 2015 to 2021: 22 males (62.9%) and 13
females (37.1%). The mean age was 43.8 + 13.1 years. The majority of
subjects were 18–40 years and 40–60 years; about 15 subjects (42.9%).
The majority of body mass index (BMI) was classified as underweight,
with 16 subjects (45.7%), followed by normal weight, and the least was
the obese group, which only had one subject. Malignancy was the most
indication of surgery, consisting of 24 subjects (68.6%), mainly in the
stage III group (11 subjects, 31.4%), the most common histopathology
was adenocarcinoma (21 subjects, 60.0%), and the number of patients
with a history of chemotherapy reached 18 (51.4% of all subjects or
75.0% of all patients diagnosed with malignancy). The one–third lower
distal part was the most common (23 subjects, 65.7%) pathological site,
either due to tumor, trauma, caustic/corrosive injury, or other non–
malignancy etiology. This also contributed to the high number of
esophagectomies at the distal level. The type of esophageal
reconstruction after esophagectomy performed at CMGH consisted of
11 (31.4%) gastric pull–ups and 24 (68.6%) other types. These other
types included ileal conduit, colon conduit, and gastroesophageal
anastomosis.
Quality of life after esophagectomy
The median quality of life (global health) of all subjects in this study was
83.3 (IQR: 25.0). Based on the functional scale group on the C30
questionnaire, which consists of elements of physical functioning (PF),
role functioning (RF), emotional functioning (EF), and social
functioning (SF), the median value was 93.3 (IQR: 33.3), 100.0 (IQR:
33.3), 83.3 (IQR: 26.7), and 100.0 (IQR: 0.0), respectively. These four
groups of items had high value. Only the cognitive functioning (CF)

Variables
Age, mean (SD)
Age group
18–40
40–60
>60
Gender
Male
Female
Body mass index
Underweight
Normal
Overweight
Obese
Indication of surgery
Malignancy
Non–malignancy
Tumor stage
I
II
III
IV
Pathological site
Upper third
Middle third
Lower third
Esophagectomy level
Distal
Partial
Total
Reconstruction type
Gastric pull up
Others
Histopathological type
Adenocarcinoma
Squamous cell carcinoma
Non–cancer
Chemotherapy
Yes
No

Subjects (n = 35)

%

43.8 + 13.1 years
15
15
5

42.9%
42.9%
14.2%

22
13

62.9%
37.1%

16
14
4
1

45.7%
40.0%
11.4%
2.9%

24
11

68.6%
31.4%

0
7
11
6

0.0%
20.0%
31.4%
17.1%

8
4
23

22.9%
11.4%
65.7%

23
0
12

65.7%
0.0%
34.3%

11
24

31.4%
68.6%

21
3
11

60.0%
8.6%
31.4%

18
17

51.4%
48.6%

In the C30 questionnaire, the question items that were statistically
significant with prognostic factors include (1) physical functioning and
gender; (2) role functioning and the tumor stage; (3) social functioning
and histopathological types; (4) pain symptoms and gender; and (5)
dyspnea symptoms and gender. Meanwhile, other prognostic factors
were not statistically significant with the item questions on the C30
questionnaire.
In the OES18 questionnaire, the question items were statistically
significant with prognostic factors, including (1) dysphagia symptoms
(OESDYS) with tumor/non–tumor location; (2) feeding symptoms
(OESEAT) with tumor/non–tumor location; (3) pain symptoms
(OESPA) with gender; (4) choking symptoms (OESCH) with
tumor/non–tumor location, esophagectomy level, esophageal
reconstruction type, and chemotherapy; (5) tasting symptom (OESTA)
with tumor/non–tumor location; (6) cough symptom (OESCO) with
2

The New Ropanasuri Journal of Surgery 2022 Volume 7 No. 2: Page 1–9

Table 2. Factors associated with the EORTC–QLQ–C30 score
GH
Variables
Median (IQR)
p

PF
Median
(IQR)
93.3 (33.3)

p

RF
Median
(IQR)
100.0 (33.3)

EF
p

Median (IQR)

p

CF
Median
(IQR)
66.7 (50.0)

SF
p

Median (IQR)

p

FA
Median
(IQR)
0.0 (23.3)

p

Overall subjects
83.3 (25.0)
83.3 (26.7)
100.0 (0.0)
Age group
0.843
0.381
0.494
0.786
0.767
0.650
0.454
18–40
83.3 (25.0)
80.0 (40.0)
100.0 (33.3)
83.3 (33.3)
66.7 (50.0)
100.0 (0.0)
10.0 (43.3)
40–60
83.3 (25.0)
93.3 (28.3)
100.0 (33.3)
90.0 (26.7)
75.0 (50.0)
100.0 (0.0)
0.0 (25.8)
>60
83.3 (0.0)
76.7 (0.0)
100.0 (0.0)
83.4 (0.0)
75.0 (0.0)
100.0 (0.0)
0.0 (0.0)
Gender
0.351
0.039*
0.119
0.231
0.075
0.860
0.076
Male
83.3 (25.0)
93.3 (26.7)
100.0 (16.7)
90.0 (26.7)
83.3 (50.0)
100.0 (0.0)
0.0 (13.3)
Female
66.7 (25.0)
73.3 (46.7)
83.3 (58.4)
73.3 (38.3)
50.0 (41.7)
100.0 (0.0)
10.0 (61.7)
Body mass index
0.463
0.517
0.335
0.299
0.756
0.757
0.822
Underweight
83.3 (25.0)
86.7 (31.7)
100.0 (33.3)
78.3 (33.3)
66.7 (33.3)
100.0 (0.0)
0.0 (27.5)
Normal
75.0 (27.1)
90.0 (43.3)
91.7 (50.0)
83.3 (30.8)
91.7 (50.0)
100.0 (0.0)
5.0 (56.7)
Overweight
87.5 (20.8)
93.3 (5.0)
100.0 (0.0)
100.0 (12.5)
75.0 (62.5)
100.0 (0.0)
5.0 (20.0)
Obese
–
–
–
–
–
–
–
Indication of surgery
0.322
0.560
0.664
0.343
0.912
0.971
0.285
Malignancy
83.3 (25.0)
93.3 (26.7)
100.0 (16.7)
100.0 (26.7)
66.7 (50.0)
100.0 (0.0)
0.0 (10.0)
Non–malignancy
83.3 (25.0)
90.0 (38.3)
100.0 (45.8)
83.3 (31.7)
75.0 (50.0)
100.0 (0.0)
5.0 (50.9)
Tumor stage
0.261
0.605
0.047*
0.243
0.605
0.402
0.057
I
–
–
–
–
–
–
–
II
83.3 (16.6)
93.3 (33.3)
100.0 (33.3)
90.0 (26.7)
83.3 (50.0)
100.0 (0.0)
0.0 (33.3)
III
83.8 (26.6)
93.3 (33.3)
100.0 (16.7)
83.3 (33.3)
66.7 (50.0)
100.0 (0.0)
0.0 (10.0)
IV
66.7 (8.3)
63.3 (55.0)
50.0 (54.2)
70.0 (32.4)
66.7 (75.0)
100.0 (16.7)
40.0 (49.2)
Pathological location
0.898
0.717
0.197
0.539
0.872
0.436
0.183
Upper third
83.3 (25.0)
73.3 (35.0)
83.3 (33.3)
81.7 (33.3)
75.0 (62.5)
100.0 (0.0)
5.0 (35.0)
Middle third
83.3 (25.0)
86.7 (28.3)
100.0 (0.0)
73.3 (25.0)
50.0 (37.5)
100.0 (0.0)
0.0 (0.0)
Lower third
83.3 (25.0)
93.3 (33.3)
100.0 (33.3)
90.0 (26.7)
83.3 (50.0)
100.0 (0.0)
10.0 (33.3)
Esophagectomy level
0.957
0.433
0.757
0.490
0.900
0.198
0.304
Distal
83.3 (25.0)
93.3 (33.3)
100.0 (33.3)
90.0 (26.7)
83.3 (50.0)
100.0 (0.0)
10.0 (33.3)
Partial
–
–
–
–
–
–
–
Total
83.3 (25.0)
76.7 (30.0)
100.0 (29.2)
73.3 (31.7)
58.4 (50.0)
100.0 (0.0)
0.0 (10.0)
Reconstruction type
0.798
0.956
0.782
0.710
0.714
0.200
0.351
Gastric pull up
83.3 (25.0)
90.0 (26.7)
100.0 (29.2)
83.3 (26.7)
83.3 (50.0)
100.0 (0.0)
10.0 (23.3)
Others
83.3 (25.0)
93.3 (33.3)
100.0 (33.3)
90.0 (33.3)
50.0 (50.0)
100.0 (0.0)
0.0 (33.3)
Histopathological type
0.595
0.642
0.908
0.537
0.620
0.001*
0.516
Adenocarcinoma
83.3 (25.0)
93.3 (26.7)
100.0 (16.7)
100.0 (26.7)
66.7 (50.0)
100.0 (0.0)
0.0 (10.0)
Squamous cell carcinoma
83.3 (25.0)
93.3 (36.7)
100.0 (41.7)
83.3 (30.0)
66.7 (50.0)
100.0 (0.0)
10.0 (45.0)
Non–cancer
83.3 (0.0)
86.7 (0.0)
100.0 (0.0)
73.3 (0.0)
100.0 (0.0)
83.3 (0.0)
0.0 (0.0)
Chemotherapy
0.919
0.565
0.633
0.447
0.878
0.563
0.287
Yes
83.3 (50.0)
90.0 (35.0)
100.0 (37.5)
83.3 (33.3)
75.0 (50.0)
100.0 (0.0)
10.0 (39.2)
No
83.3 (25.0)
93.3 (26.7)
100.0 (25.0)
90.0 (26.7)
66.7 (50.0)
100.0 (0.0)
0.0 (16.7)
Notes: GH = global health; PF = physical functioning; RF = role functioning; EF = emotional functioning; CF = cognitive functioning; SF = social functioning; FA = fatigue; NV = nausea and vomiting; PA = pain; DY = dyspnea; SL = insomnia; AP = appetite loss; CO = constipation;
DI = diarrhea; FI = financial difficulties; IQR = interquartile range; * = significant (p <0.05)
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Table 2. Factors associated with the EORTC–QLQ–C30 score (cont.)
NV
Variables

Median
(IQR)

Overall subjects

16.7 (50.0)

Age group
18–40
40–60
>60

16.7 (50.0)
0.0 (50.0)
25.0 (0.0)

Gender
Male
Female

8.4 (37.5)
33.3 (66.7)

Body mass index
Underweight
Normal
Overweight
Obese

16.7 (33.3)
8.4 (50.0)
25.0 (50.0)
–

Indication of surgery
Malignancy
Non–malignancy

16.7 (50.0)
16.7 (50.0)

Tumor stage
I
II
III
IV

–
16.7 (50.0)
16.7 (33.3)
33.4 (66.7)

Pathological location
Upper third
Middle third
Lower third

0.0 (29.2)
25.0 (41.7)
16.7 (50.0)

Esophagectomy level
Distal
Partial
Total

16.7 (50.0)
–
8.4 (33.3)

Reconstruction type
Gastric pull up
Others

16.7 (50.0)
0.0 (50.0)

Histopathological type
Adenocarcinoma
Squamous cell carcinoma
Non–cancer

16.7 (50.0)
16.7 (50.0)
16.7 (0.0)

Chemotherapy
Yes
No

16.7 (50.0)
0.0 (50.0)

p

PA
Median
(IQR)

p

16.7 (33.3)

0.772

0.085

0.963

0.985

0.561

0.476

0.381

0.641

0.892

16.7 (0.0)
16.7 (33.3)
8.4 (0.0)

16.7 (16.7)
16.7 (33.3)

16.7 (29.2)
16.7 (20.8)
8.4 (16.7)
–
16.7 (16.7)
16.7 (33.3)
–
16.7 (33.3)
16.7 (16.7)
33.3 (29.1)

16.7 (25.0)
8.4 (16.7)
16.7 (33.3)

16.7 (33.3)
–
16.7 (16.7)

16.7 (12.5)
16.7 (33.3)
16.7 (16.7)
16.7 (33.3)
16.7 (0.0)

0.478

0.024*

0.503

0.393

0.111

0.399

0.458

0.955

0.679

DY
Media
n
(IQR)
0.0 (0.0)
0.0
(33.3)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0
(50.0)
0.0 (0.0)
0.0
(33.3)
0.0 (0.0)
–
0.0 (0.0)
0.0 (0.0)
–
0.0 (0.0)
0.0 (0.0)
0.0
(41.7)
0.0
(33.3)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
–
0.0
(25.0)
0.0 (0.0)
0.0
(33.3)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

SL
p

Median
(IQR)

AP
p

0.0 (66.7)

0.414

0.009*

0.481

0.957

0.505

0.220

0.427

0.255

0.818

0.0 (66.7)
16.7 (66.7)
0.0 (0.0)

0.0 (66.7)
0.0 (50.0)

0.0 (58.4)
0.0 (66.7)
0.0 (75.0)
–
0.0 (33.3)
0.0 (66.7)
–
0.0 (66.7)
0.0 (33.3)
50.0 (50.1)

0.0 (58.4)
0.0 (0.0)
0.0 (66.7)

0.0 (66.7)
–
0.0 (58.4)

0.0 (66.7)
0.0 (33.3)
0.0 (33.3)
0.0 (66.7)
0.0 (0.0)

Median
(IQR)

CO
p

0.0 (33.3)

0.393

0.757

0.853

0.364

0.136

0.215

0.541

0.572

0.661

0.0 (0.0)
0.0 (33.3)
33.3 (0.0)

0.0 (33.3)
0.0 (33.3)

0.0 (33.3)
0.0 (33.3)
0.0 (25.0)
–
0.0 (33.3)
0.0 (33.3)
–
0.0 (33.3)
0.0 (33.3)
0.0 (66.7)

0.0 (25.0)
0.0 (25.0)
0.0 (33.3)

0.0 (33.3)
–
0.0 (33.3)

0.0 (33.3)
0.0 (33.3)
0.0 (33.3)
0.0 (33.3)
0.0 (0.0)

Median
(IQR)

DI
p

0.0 (0.0)

0.144

0.640

0.676

0.597

0.873

0.736

0.868

0.597

0.325

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

0.0 (0.0)
0.0 (0.0)

0.0 (0.0)
0.0 (0.0)
0.0 (50.0)
–
0.0 (0.0)
0.0 (0.0)
–
0.0 (0.0)
0.0 (0.0)
0.0 (8.3)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

0.0 (0.0)
–
0.0 (0.0)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

Median
(IQR)

FI
p

0.0 (0.0)

0.834

0.833

0.377

0.913

0.587

0.761

1.000

0.227

0.861

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

0.0 (0.0)
0.0 (0.0)

0.0 (0.0)
0.0 (66.7)
0.0 (25.0)
–
0.0 (0.0)
0.0 (0.0)
–
0.0 (0.0)
0.0 (0.0)
0.0 (8.3)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

0.0 (0.0)
–
0.0 (0.0)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
00 (0.0)

Median
(IQR)

p

0.0 (66.7)

0.868

0.665

0.720

0.847

0.895

0.752

0.753

0.847

0.501

33.3 (66.7)
0.0 (66.7)
0.0 (0.0)

0.0 (66.7)
0.0 (0.0)

33.3 (91.7)
0.0 (66.7)
0.0 (50.0)
–
0.0 (66.7)
16.7 (66.7)
–
66.7 (100.0)
0.0 (66.7)
16.7 (75.0)

66.7 (91.7)
0.0 (75.0)
0.0 (66.7)

0.0 (66.7)
–
50.0 (100.0)

0.0 (66.7)
33.3 (100.0)
0.0 (66.7)
0.0 (66.7)
33.3 (0.0)

0.425

0.807

0.443

0.379

0.299

0.131

0.157

0.118

0.342

0.0 (0.0)
0.339
16.7 (66.7)
0.303
0.0 (33.3)
0.680
0.0 (0.0)
0.610
0.0 (0.0)
0.905
0.0 (66.7)
0.772
0.0
0.0 (50.0)
0.0 (33.3)
0.0 (0.0)
0.0 (0.0)
0.0 (83.4)
(16.7)
Notes: GH = global health; PF = physical functioning; RF = role functioning; EF = emotional functioning; CF = cognitive functioning; SF = social functioning; FA = fatigue; NV = nausea and vomiting; PA = pain; DY = dyspnea; SL = insomnia; AP = appetite loss; CO = constipation;
DI = diarrhea; FI = financial difficulties; IQR = interquartile range; * = significant (p <0.05)
0.544

16.7 (33.3)
16.7 (16.7)

0.492
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Table 3. Factors associated with the EORTC–QLQ–OES18 score
OESDYS
OESEAT
OESRFX
OESPA
OESSV
Variables
Median (IQR)
p
Median (IQR)
p
Median (IQR)
p
Median (IQR)
p
Median (IQR)
p
Overall subjects
33.3 (33.3)
34.5 (23.9)
16.7 (33.3)
23.3 (33.3)
0.0 (66.7)
Age group
18–40
23.3 (46.7)
40.9 (26.8)
33.3 (33.3)
33.3 (23.3)
0.0 (66.7)
0.426
0.310
0.826
0.114
0.455
40–60
33.3 (23.3)
30.9 (21.4)
0.0 (50.0)
10.0 (33.3)
0.0 (66.7)
>60
16.7 (0.0)
18.4 (11.8)
16.7 (0.0)
5.0 (0.0)
0.0 (0.0)
Gender
Male
28.3 (39.2)
0.809
29.3 (22.7)
0.092
0.0 (37.5)
0.148
10.0 (25.8)
0.007*
0.0 (41.7)
0.477
Female
33.3 (33.3)
43.3 (23.9)
33.3 (33.3)
33.3 (16.7)
0.0 (66.7)
Body mass index
Underweight
28.3 (20.0)
38.6 (24.4)
8.4 (33.3)
16.7 (33.3)
0.0 (58.4)
Normal
23.3 (35.8)
0.237
31.7 (21.6)
0.116
16.7 (37.5)
0.846
23.3 (33.3)
0.503
0.0 (66.7)
0.252
Overweight
55.0 (78.4)
17.5 (18.5)
25.0 (62.5)
21.7 (38.3)
0.0 (0.0)
Obese
–
–
–
–
–
Indication of surgery
Malignancy
33.3 (43.4)
0.166
41.2 (24.9)
0.264
16.7 (33.3)
1.000
23.3 (23.3)
0.812
33.3 (66.7)
0.202
Non–malignancy
23.3 (33.3)
31.4 (23.3)
16.7 (45.8)
23.3 (33.3)
0.0 (33.3)
Tumor stage
I
–
–
–
–
–
II
33.3 (20.0)
0.307
42.9 (22.1)
0.126
33.3 (50.0)
0.481
10.0 (33.3)
0.732
0.0 (33.3)
0.575
III
10.0 (23.3)
21.2 (24.6)
16.7 (50.0)
10.0 (43.3)
0.0 (0.0)
IV
38.3 (39.2)
36.7 (15.8)
0.0 (25.0)
28.3 (15.8)
16.7 (66.7)
Pathological location
Upper third
50.0 (58.4)
60.4 (25.1)
8.4 (45.8)
16.7 (40.8)
33.3 (66.7)
0.048*
0.001*
0.725
0.495
0.181
Middle third
28.3 (60.0)
20.0 (8.2)
8.4 (29.2)
5.0 (27.5)
0.0 (0.0)
Lower third
23.3 (33.3)
27.9 (18.5)
16.7 (50.0)
23.3 (33.3)
0.0 (66.7)
Esophagectomy level
Distal
23.3 (33.3)
30.1 (21.8)
16.7 (50.0)
23.3 (33.3)
0.0 (33.3)
0.085
0.138
0.484
0.497
0.421
Partial
–
–
–
–
–
Total
38.3 (60.9)
42.8 (26.3)
8.4 (33.3)
10.0 (33.3)
16.7 (66.7)
Reconstruction type
Gastric pull up
23.3 (33.3)
0.350
31.1 (22.9)
0.233
16.7 (33.3)
0.970
23.3 (33.3)
0.622
0.0 (58.4)
1.000
Others
33.3 (20.0)
41.8 (25.2)
16.7 (50.0)
10.0 (33.3)
0.0 (66.7)
Histopathological type
Adenocarcinoma
33.3 (43.4)
41.2 (24.9)
16.7 (33.3)
23.3 (23.3)
33.3 (66.7)
0.248
0.434
0.790
0.947
0.436
Squamous cell carcinoma
23.3 (33.3)
30.2 (23.2)
16.7 (50.0)
23.3 (33.3)
0.0 (50.0)
Non–cancer
33.3 (0.0)
40.0 (26.5)
0.0 (0.0)
23.3 (0.0)
0.0 (0.0)
Chemotherapy
Yes
23.3 (33.3)
0.176
22.6 (17.1)
0.001
8.4 (37.5)
0.529
23.3 (33.3)
0.825
0.0 (41.7)
0.379
No
33.3 (38.4)
47.1 (23.9)
33.3 (41.7)
23.3 (28.3)
0.0 (66.7)
Notes: OESDYS = dysphagia, OESEAT = eating, OESRFX = reflux, OESPA = pain, OESSV = trouble swallowing saliva, OESCH = choking, OESDM = dry mouth, OESTA = taste, OESCO = cough, OESSP = speech, IQR = interquartile range, * = significant (p <0.05).
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Table 3. Factors associated with the EORTC–QLQ–OES18 score (cont.)
OESCH
OESDM
OESTA
OESCO
OESSP
Variables
Median (IQR)
p
Median (IQR)
p
Median (IQR)
P
Median (IQR)
p
Median (IQR)
p
Overall subjects
33.3 (33.3)
0.0 (33.3)
0.0 (0.0)
33.3 (33.3)
0.0 (0.0)
Age group
18–40
33.3 (33.3)
33.3 (33.3)
0.0 (66.7)
33.3 (66.7)
0.0 (33.3)
0.829
0.109
0.421
0.770
0.081
40–60
33.3 (33.3)
0.0 (8.3)
0.0 (0.0)
33.3 (41.7)
0.0 (0.0)
>60
16.7 (0.0)
0.0 (0.0)
0.0 (0.0)
16.7 (0.0)
0.0 (0.0)
Gender
Male
16.7 (33.3)
0.352
0.0 (33.3)
0.291
0.0 (0.0)
0.471
33.3 (41.7)
0.942
0.0 (0.0)
0.435
Female
33.3 (33.3)
0.0 (33.3)
0.0 (50.0)
33.3 (50.0)
0.0 (16.7)
Body mass index
Underweight
33.3 (33.3)
0.0 (33.3)
0.0 (83.3)
33.3 (58.4)
0.0 (0.0)
Normal
33.3 (33.3)
0.900
0.0 (41.7)
0.333
0.0 (0.0)
0.187
33.3 (33.3)
0.623
0.0 (0.0)
0.257
Overweight
16.7 (33.3)
0.0 (0.0)
0.0 (0.0)
33.3 (50.0)
0.0 (25.0)
Obese
–
–
–
–
–
Indication of surgery
Malignancy
33.3 (66.7)
0.121
0.0 (33.3)
0.569
0.0 (66.7)
0.645
33.3 (33.3)
0.649
0.0 (33.3)
0.045
Non–malignancy
16.7 (33.3)
0.0 (33.3)
0.0 (0.0)
33.3 (58.4)
0.0 (0.0)
Tumor stage
I
–
–
–
–
–
II
33.3 (0.0)
0.101
0.0 (0.0)
0.115
0.0 (100.0)
0.494
33.3 (66.7)
0.259
0.0 (0.0)
0.587
III
0.0 (33.3)
0.0 (0.0)
0.0 (0.0)
33.3 (33.3)
0.0 (0.0)
IV
0.0 (33.3)
33.3 (75.0)
0.0 (41.7)
33.3 (50.0)
0.0 (8.3)
Pathological location
Upper third
50.0 (58.4)
33.3 (58.4)
83.4 (100.0)
16.7 (66.7)
16.7 (100.0)
0.029*
0.103
0.005*
0.205
0.009*
Middle third
33.3 (0.0)
0.0 (0.0)
0.0 (0.0)
50.0 (58.4)
0.0 (25.0)
Lower third
0.0 (33.3)
0.0 (33.3)
0.0 (0.0)
33.3 (33.3)
0.0 (0.0)
Esophagectomy level
Distal
0.0 (33.3)
0.0 (33.3)
0.0 (0.0)
33.3 (33.3)
0.0 (0.0)
0.023*
0.757
0.246
0.504
0.072
Partial
–
–
–
–
–
Total
33.3 (25.1)
0.0 (33.3)
0.0 (91.7)
33.3 (66.7)
0.0 (33.3)
Reconstruction type
Gastric pull up
0.0 (33.3)
0.007*
0.0 (33.3)
0.598
0.0 (0.0)
0.121
33.3 (33.3)
0.012*
0.0 (0.0)
0.914
Others
33.3 (33.4)
0.0 (66.7)
0.0 (100.0)
33.3 (33.4)
0.0 (0.0)
Histopathological type
Adenocarcinoma
33.3 (66.7)
0.0 (33.3)
0.0 (66.7)
33.3 (33.3)
0.0 (33.3)
0.285
0.119
0.718
0.168
0.076
Squamous cell carcinoma
0.0 (33.3)
0.0 (16.7)
0.0 (0.0)
33.3 (33.3)
0.0 (0.0)
Non–cancer
33.3 (0.0)
100.0 (0.0)
0.0 (0.0)
66.7 (0.0)
0.0 (0.0)
Chemotherapy
Yes
0.0 (33.3)
0.007*
0.0 (33.3)
0.399
0.0 (0.0)
0.056
33.3 (33.3)
0.470
0.0 (0.0)
0.056
No
33.3 (50.1)
0.0 (33.3)
0.0 (100.0)
33.3 (66.7)
0.0 (33.3)
Notes: OESDYS = dysphagia, OESEAT = eating, OESRFX = reflux, OESPA = pain, OESSV = trouble swallowing saliva, OESCH = choking, OESDM = dry mouth, OESTA = taste, OESCO = cough, OESSP = speech, IQR = interquartile range, * = significant (p <0.05).
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esophageal reconstruction type; and (7) speech symptoms (OESSP)
with tumor/nontumor location. Other prognostic factors were not
statistically significant with the item questions on the OES18
questionnaire.

these items have varying IQR scores. Therefore, there is still the
possibility of differences in the degree of symptoms reported by
patients.28 All the results in C30 and OES18 scores should be affected
or related by some factors, including gender, tumor stage,
histopathological types, tumor location, and reconstruction type.

Discussion
In this study, most subjects were male, as in several similar studies in
Sweden,25 Texas,26 Germany,27,28 and Seattle.29 However, the mean age
of the subjects in this study was younger than the mean age in those five
studies. After being grouped by age, the patient population at CMGH,
esophageal cancer that requires an esophagectomy procedure is more
likely to occur at a young age. Most subjects had underweight and
normal body mass index (BMI), thus slightly different from Poh et al.,
who showed that the subject population consisted of patients with
normal BMI.26 The low BMI of patients at the CMGH should be
suspected because most patients have trouble with food intake due to
obstruction in the esophagus.
Esophagectomy remains the primary choice in resectable esophageal
cancer.9 Most esophagectomy was performed at the distal level,
corresponding to the most common pathological location in the lower
third. This finding is similar to the results of a study by Gockel et al.,
which was also dominated by 62% of patients with distal tumor
locations.28 The most common histopathological type found in this study
was adenocarcinoma. It is different from the study in Germany by
Gockel et al., which was dominated by squamous cell carcinoma.28
However, another study conducted in Germany by Gutschow et al.
showed that 68.7% of patients had adenocarcinoma cell type cancer.27
More than 50% of patients in CMGH were known to have received
chemotherapy before the surgical procedure compared to those who did
not. The high number of subjects who received chemotherapy could be
attributed to many patients with advanced malignancy. A study in
Germany by Gutschow et al. showed that the percentage of patients who
received neoadjuvant therapy such as radiotherapy or chemotherapy
was less than 50% because the early tumor stages dominated the
population.27
Quality of life after esophagectomy and its associated factors
The quality of life of post–esophagectomy patients at CMGH is quite
good. Global health item scores are higher than the study by Gockel et
al., which only had a median of 83.3,28, also higher than Gutschow et al.
and the reference value from EORTC.27 In this study, the lowest score
in the C30 functional scale item questionnaire was cognitive functioning
(CF). At the same time, the highest scores were role functioning (RF)
and social functioning (SF). This result differs from Gockel et al., which
showed that the highest score was on CF items, and the lowest was on
RF and SF items.28 The CF score of this study is even lower than the
reference value from EORTC.27 In this study, the C30 questionnaire for
symptoms, nausea, vomitus (NV), and pain (PA) had the highest score.
In the study by Gockel et al., PA items were also reported by some
patients, although their values were lower than in this study.28 The NV
symptom score in this study is higher than the reference value from
EORTC.27
The results of symptom scores on the OES18 questionnaire are also
similar to the results of a study by Gockel et al. Trouble swallowing
saliva (OSSV), dry mouth (OESDM), taste (OESTA), and speech
(OESSP) items all scored 0. Reflux (OESRFX) and pain (OESPA) were
also common symptoms. The different results were dysphagia
(OESDYS), eating (OESEAT), choking (OESCH), and coughing
(OESCO) items which were zero in the study by Gockel et al. but were
widely reported in this study. Although many items have zero scores,

Gender was significantly related to the C30 questionnaire score on
physical functioning, pain, and dyspnea symptoms. The male gender
had a higher median physical functioning than the female. While the
median value on symptom items did not differ, both scores were zero
and statistically significant. A study in Sweden by Djarv et al. showed
that the median score in male patients was higher than that of female
patients. Although based on statistical analysis, both gender is worse off
than their population's reference score.15
The tumor stage was significantly related to role functioning. Subjects
with tumor stage IV had the lowest median score = 50 (IQR: 54.2). The
low score of the role functioning items can be suspected as a result of
patients following routine chemotherapy and periodic controls, thus
limiting them from being more active in the community, which
decreases their quality of life. Although the study by Gutschow et al.
failed to demonstrate the effect of tumor stage on quality of life.27
Histopathological types were significantly related to social functioning.
Squamous cell carcinoma had a lower score than adenocarcinoma. A
study that found the relationship between histopathological types and
quality of life was conducted by Gockel et al. However, the related item
was pain based on the OES18 questionnaire. Squamous cell carcinoma
is significantly associated with a higher score of pain symptom
complaints than adenocarcinoma.28 The high score of pain may
indirectly affect the social functioning item. Even though in this study,
the histopathological type was significantly associated with pain
symptoms. However, the female factor had a higher median pain score
than the male one.
Tumor location was significantly related to many items in the OES18
questionnaire, starting from dysphagia (OESDYS), eating (OESEAT),
choking (OESCH), tasting (OESTA), and speech (OESSP). The tumor
location that triggers more of these symptoms is the upper third. It is
suspected that this is related to the function of the epiglottis, larynx, and
tongue, which are located more proximal.
In this study, gastric pull–up reconstruction had a higher median score
than other techniques (jejunal conduit, distal gastroesophageal
anastomosis, colon conduit). It was statistically significant (p = 0.007)
on the OESCH and OESCO items in the OES18 questionnaire. OESCH
is a parameter to assess complaints of choking when eating, and OESCO
is a parameter to assess cough problems. The two are interconnected
because the choking state will trigger a cough response. The inability to
cough can worsen the choking condition. Based on the study by
Stephens et al., complaints of reflux, dumping, or dysphagia after gastric
pull–up procedures should not be different from other reconstruction
techniques.30 Although the gastric pull–up technique is relatively easy to
perform, the outcome of this procedure is associated with frequent
complaints of reflux, uncontrolled gastric emptying, and various other
postprandial symptoms.31 This reflux state continues to cause dysphagia.
However, the 10–year QOL following esophagectomy with esophageal
reconstruction using the gastric pull–up technique showed better results.
Patient satisfaction in consuming their food increases, and their
postprandial symptoms improve.32
The limitation of this study is the lack of literature that discusses the
relationship between each prognostic factor and quality of life items.
Furthermore, most published studies only convey the overall median
7
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QoL without stratification. Therefore, measuring the quality of life was
proceeded only once and without precise boundaries/intervals—for
example, three months and six months after esophagectomy. In addition,
this study had not collected baseline QoL values from the normal
population in CMGH and Indonesia. Thus, they still had to rely on
references from EORTC and other research that could give inaccurate
results.

8.

9.

10.

Conclusions
11.

The overall quality of life in patients after esophagectomy at CMGH
based on the EORTC–QLQ–C30 and OES18 questionnaires were
good. Prognostic factors associated with decreased quality of life should
be better educated to patients and prepared well before the
esophagectomy procedure, thus maximizing quality of life after
esophagectomy. Quality of life assessment should be carried out in
patients after esophagectomy procedure at certain time intervals and
more than one measurement.
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